Cirius Therapeutics Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
11
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$2.3M
- Investors
-
3
Cirius Therapeutics General Information
Description
Developer of an insulin sensitizer drug designed for the treatment of nonalcoholic liver disease. The company's sensitizer drug is used to treat nonalcoholic steatohepatitis which is characterized by the buildup of fat and inflammation in the liver, may be accompanied by fibrosis and can progress to life-threatening cirrhosis or liver cancer, enabling healthcare providers to treat patients with liver and metabolic diseases and avoid recurrence of nonalcoholic steatohepatitis.
Contact Information
Website
www.ciriustx.comCorporate Office
- 3133 Orchard Vista Drive South East
- Grand Rapids, MI 49546
- United States
Corporate Office
- 3133 Orchard Vista Drive South East
- Grand Rapids, MI 49546
- United States
Cirius Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Later Stage VC | 08-Oct-2024 | $2.3M | Completed | Generating Revenue | ||
| 6. Secondary Transaction - Private | 01-Feb-2024 | Completed | Generating Revenue | |||
| 5. IPO | 20-Dec-2019 | Cancelled | Generating Revenue | |||
| 4. Early Stage VC (Series A3) | 10-May-2019 | Completed | Generating Revenue | |||
| 3. Early Stage VC (Series A3) | 23-Aug-2018 | Completed | Startup | |||
| 2. Early Stage VC (Series A2) | 10-Apr-2017 | $40M | $56.4M | Completed | Startup | |
| 1. Early Stage VC (Series A1) | 19-May-2016 | $16.4M | $16.4M | Completed | Startup |
Cirius Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A3 | ||||||||
| Series A2 | ||||||||
| Series A1 | 17,069,451 | $0.001000 | 8% | $1 | $1 | 1x | $1 | 17.25% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Cirius Therapeutics Comparisons
Industry
Financing
Details
Cirius Therapeutics Competitors (86)
One of Cirius Therapeutics’s 86 competitors is OrphoMed, a Venture Capital-Backed company based in San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| OrphoMed | Venture Capital-Backed | San Francisco, CA | ||||
| Hepion Pharmaceuticals | Corporation | Edison, NJ | ||||
| Galecto | Formerly VC-backed | Copenhagen, Denmark | ||||
| BioVie | Formerly VC-backed | Carson City, NV | ||||
| Intercept Pharmaceuticals | Formerly VC-backed | Morristown, NJ |
Cirius Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Cirius Therapeutics Patents
Cirius Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20230210825-A1 | Methods and compositions for treating subjects with metabolic disorders and coronavirus infections | Pending | 17-Apr-2020 | ||
| US-20230013627-A1 | Thiazolidinedione analogs for the treatment of nafld and metabolic diseases | Pending | 08-Nov-2019 | ||
| EP-4054568-A1 | Thiazolidinedione analogs for the treatment of nafld and metabolic diseases | Inactive | 08-Nov-2019 | ||
| EP-4054568-A4 | Thiazolidinedione analogs for the treatment of nafld and metabolic diseases | Inactive | 08-Nov-2019 | ||
| US-20240216344-A1 | Thiazolidinedione analogs for the treatment of nafld and metabolic diseases | Inactive | 08-Nov-2019 | A61K31/426 |
Cirius Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Cirius Therapeutics Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Frazier Healthcare Partners | PE/Buyout | Minority | ||
| Novo Holdings | Corporate Venture Capital | Minority | ||
| Renaissance Venture Capital | Fund of Funds | Minority |
Cirius Therapeutics Investments (1)
Cirius Therapeutics’s most recent deal was a Early Stage VC with MetaSight. The deal was made on 01-Apr-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| MetaSight | 01-Apr-2022 | Early Stage VC | Biotechnology |
Cirius Therapeutics FAQs
-
When was Cirius Therapeutics founded?
Cirius Therapeutics was founded in 2015.
-
Where is Cirius Therapeutics headquartered?
Cirius Therapeutics is headquartered in Grand Rapids, MI.
-
What is the size of Cirius Therapeutics?
Cirius Therapeutics has 11 total employees.
-
What industry is Cirius Therapeutics in?
Cirius Therapeutics’s primary industry is Pharmaceuticals.
-
Is Cirius Therapeutics a private or public company?
Cirius Therapeutics is a Private company.
-
What is Cirius Therapeutics’s current revenue?
The current revenue for Cirius Therapeutics is .
-
How much funding has Cirius Therapeutics raised over time?
Cirius Therapeutics has raised $71.2M.
-
Who are Cirius Therapeutics’s investors?
Frazier Healthcare Partners, Novo Holdings, and Renaissance Venture Capital have invested in Cirius Therapeutics.
-
Who are Cirius Therapeutics’s competitors?
OrphoMed, Hepion Pharmaceuticals, Galecto, BioVie, and Intercept Pharmaceuticals are some of the 86 competitors of Cirius Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
